Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...

The company's product portfolio includes Udenyca, a biosimilar to Neulasta, and the recently launched Loqtorzi (toripalimab), a PD-1 inhibitor targeting various cancers. This dual focus on ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Biosimilar competition continues to impose challenges, notably impacting legacy products like Neulasta and Enbrel. The sales of these drugs have eroded due to competitive pricing from biosimilar ...

It is now widely recognized that Pegfilgrastim biosimilars, such as Neulasta, hold a pivotal role in preventing chemotherapy-induced neutropenia in cancer patients by promoting the production of ...